Leflunomide Tablet, Film Coated
Product Images NDC 70771-1492

8 FDA label images from Zydus Lifesciences Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 70771-1492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 03)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 03)
Chemical structure of leflunomide, depicting its molecular arrangement including a trifluoromethyl-substituted aromatic ring, an amide linkage, and an isoxazole ring with methyl substitution.*
FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 04)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 04)
Chemical structure of teriflunomide (A77 1726), the active metabolite of leflunomide, depicted with molecular bonds and functional groups including trifluoromethyl and cyano groups.*
FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 05)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 05)
A bar chart titled '% ACR 20 Responder at Endpoint' displays response percentages in three clinical trials comparing leflunomide, methotrexate, placebo, and sulfasalazine at various time points (6 to 12 months). Percentages for each treatment group are represented by black or striped bars, showing comparative efficacy endpoints.*
FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 06)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 06)
A line chart titled 'Trial 1 ACR Responders Over Time' illustrating the percentage of responders over a 12-month period for three groups: placebo (PL), methotrexate (MTX), and leflunomide (LEF). The y-axis shows percentage responders from -10 to 70, and the x-axis shows months from 0 to 12. The LEF group shows the highest response percentage over time.*
FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 07)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 07)
A bar chart titled 'Change in Sharp Score' depicting progression values for three clinical trials over 6 to 12 months. It compares the effects of Leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P), showing numerical progression values for each treatment group in the trials.*
FDA Label Image

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 08)

Image (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 08)
A bar chart titled 'Change in Functional Ability Measure' showing improvement scores measured by the HAQ Disability Index for Leflunomide, Methotrexate, and Placebo across three trials of varying durations. The chart compares the effects of these treatments over 6 to 12 months, highlighting differences in functional ability among the groups.*
FDA Label Image

Label (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 02)

Label (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 02)
Label for Leflunomide Tablets, USP 10 mg film-coated tablets in a 100-tablet package, manufactured by Zydus Lifesciences Limited. The label includes dosage strength, storage instructions at 20° to 25°C, child-resistant packaging notice, and a barcode. The product is Rx only.*
FDA Label Image

Label (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 01)

Label (Ef59c815 A437 4a63 B8fc 7d5dfa597ccd 01)
Label for leflunomide tablets, USP 20 mg, film-coated oral tablets by Zydus Lifesciences Limited. The label shows NDC 70771-1492-1 and specifies a 100 tablet count. Storage instructions, dosage advisory, and child-resistant packaging warnings are included along with manufacturer details in Baddi, India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.